Aspirin for Coronary Artery Disease: Strong Evidence for Secondary Prevention
Aspirin 75-162 mg daily is definitively recommended for all patients with established coronary artery disease unless contraindicated, based on Level A evidence showing significant reduction in cardiovascular events. 1
Core Recommendation
For patients with documented CAD—including those with prior myocardial infarction, prior revascularization (PCI or CABG), or imaging-confirmed significant obstructive disease—aspirin should be initiated and continued indefinitely. The evidence supporting this is robust and consistent across multiple high-quality guidelines.
Dosing Specifics
- Standard dose: 75-162 mg daily 1
- Post-PCI preference: 81 mg daily (lower doses reduce bleeding without compromising efficacy) 1
- Post-CABG: 100-325 mg daily for 1 year, started within 6 hours of surgery to reduce saphenous vein graft closure 1
When Aspirin Cannot Be Used
Clopidogrel 75 mg daily is the recommended alternative for patients with aspirin intolerance or allergy (Level B evidence) 1. Recent evidence suggests clopidogrel may actually be superior to aspirin in stable CAD, showing better MACE reduction (HR 0.73) and lower bleeding risk (HR 0.63) 2, 3, though this represents newer data that has not yet been fully incorporated into all guidelines.
Dual Antiplatelet Therapy (DAPT) Scenarios
After acute coronary syndrome or PCI with stenting, aspirin plus a P2Y12 inhibitor is mandatory 1:
- Duration: At least 12 months for ACS or drug-eluting stents 1
- Options: Clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor 90 mg twice daily 1
- After 12 months: Transition to aspirin monotherapy (or clopidogrel if aspirin-intolerant) 4
Early Discontinuation Considerations
DAPT may be shortened to 1-3 months if bleeding risk substantially outweighs ischemic risk, though this carries higher cardiovascular event risk with drug-eluting stents 1.
Special Populations
Peripheral Artery Disease or Prior Stroke
Aspirin 75-325 mg daily OR clopidogrel 75 mg daily should be used 1. Clopidogrel may be preferred in symptomatic cases 4.
Patients Requiring Anticoagulation
When atrial fibrillation, mechanical valves, or venous thromboembolism necessitate warfarin:
- Add low-dose aspirin 75-81 mg daily to anticoagulation 1
- Target lower INR (2.0-2.5) when combining with antiplatelet therapy to reduce bleeding 5
- Monitor closely for bleeding, especially gastrointestinal 5
Diabetes
Aspirin is recommended for secondary prevention in diabetic patients with established CAD using the same dosing as non-diabetics 6. For primary prevention in diabetes without CAD, aspirin is generally not recommended due to unfavorable risk-benefit ratio 6.
Chronic Kidney Disease
For secondary prevention in non-dialysis CKD, aspirin reduces myocardial infarction risk despite increased bleeding, and KDIGO guidelines recommend it unless excessive bleeding risk exists 7. In dialysis-dependent patients, evidence is insufficient to support routine use 7.
Critical Contraindications and Warnings
Absolute contraindications (FDA labeling) 8:
- Active pathological bleeding
- Severe allergic reaction history (hives, facial swelling, asthma, shock)
- Children/teenagers with viral illness (Reye's syndrome risk)
- Last trimester of pregnancy (unless specifically directed by physician)
Relative contraindications requiring careful assessment:
- Age ≥60 years with history of ulcers or GI bleeding
- Concurrent anticoagulation or other NSAIDs
- ≥3 alcoholic drinks daily
- Severe renal impairment
Age-Related Efficacy Concerns
Emerging evidence suggests aspirin efficacy may diminish in patients ≥65 years, with a 4-fold increased risk of MACE compared to younger patients despite treatment 9. However, current guidelines do not modify recommendations based on age alone for secondary prevention. The risk-benefit calculation remains favorable in established CAD across age groups.
What NOT to Do
- Do not use aspirin for primary prevention in low-risk individuals without established CAD—bleeding risk outweighs uncertain benefit 6, 10
- Do not combine aspirin with NSAIDs or COX-2 inhibitors in ACS patients—discontinue these immediately 11
- Do not use dual P2Y12 inhibitors simultaneously (e.g., clopidogrel + ticagrelor) 11
- Do not prefer anticoagulation over antiplatelet therapy for atherosclerosis treatment unless compelling indication exists 1
Monitoring and Follow-up
Watch for signs of bleeding (especially GI: black stools, coffee-ground emesis) and seek immediate evaluation if occurs 5. Consider proton pump inhibitor co-therapy in high-risk bleeding patients, though this is not universally required.
The evidence base strongly supports aspirin as foundational therapy in CAD, with the primary clinical decision being whether to use aspirin alone or in combination with other antithrombotic agents based on recent events, procedures, and bleeding risk assessment.